Urovant's OAB Gene Therapy Shows Improvement In Symptoms Compared To Placebo
- Urovant Sciences' interim results from a Phase 2a trial of URO-902 gene therapy were presented at the annual meeting of the American Urological Association (AUA2022).
- Urovant is a wholly-owned subsidiary of Sumitovant Biopharma Ltd.
- Sumitovant, the Sumitomo Pharma subsidiary, is also the majority shareholder of Myovant Sciences Ltd (NYSE: MYOV).
- The interim results support that in women with overactive bladder (OAB), not well managed by oral therapies, a single dose of URO-902 was safe and well-tolerated.
- Of the 80 female patients who were randomized, 68 completed week 12 of the study, and 74 were included in the intent-to-treat population.
- At week 12, both URO-902 24 mg and 48 mg were associated with a clinically relevant improvement compared with placebo in mean daily micturition (urination), urgency episodes, UUI episodes, OAB bother score, and proportion of patient global impression of change responders.
- Treatment-emergent adverse events occurred in 45.5% of patients receiving URO-902 24 mg, 46.2% receiving 48 mg, and 50.0% receiving placebo. The most commonly occurring adverse event was urinary tract infection.
- Price Action: MYOV shares are up 5.05% at $9.05 during the market session on the last check Friday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: BriefsBiotech News Health Care Small Cap Movers Trading Ideas General
